Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hedy Teppler

Showing results (21-30 of 64) with videos related to

Pageof 7
Sort By:
Current HIV Research|January 5, 2011
Long-term safety from the raltegravir clinical development programHedy Teppler, Deborah D Brown, Randi Y Leavitt, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 30, 2012
Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004)Eduardo Gotuzzo, Martin Markowitz, Winai Ratanasuwan, et al.
The Lancet. HIV|December 12, 2018
Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trialSharon Nachman, Carmelita Alvero, Hedy Teppler, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 24, 2019
Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus-1: An Integrated Safety AnalysisMelanie Thompson, Chloe Orkin, Jean-Michel Molina, et al.
Antiviral Therapy|October 29, 2014
Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infectionJoseph J Eron, David A Cooper, Roy T Steigbigel, et al.
Journal of Clinical Pharmacology|March 11, 2015
Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of ageMatthew L Rizk, Lihong Du, Chantelle Bennetto-Hood, et al.
The Journal of Antimicrobial Chemotherapy|April 26, 2005
In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART)David L Paterson, Flávia Rossi, Fernando Baquero, et al.
Journal of the International AIDS Society|November 14, 2014
Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patientsJosep M Gatell, Javier O Morales-Ramirez, Debbie P Hagins, et al.
The New England Journal of Medicine|October 2, 2004
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropeniaThomas J Walsh, Hedy Teppler, Gerald R Donowitz, et al.
The Lancet. HIV|December 23, 2023
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trialsChloe Orkin, Jean-Michel Molina, Pedro Cahn, et al.
Pageof 7

Showing results (21-30 of 64) with videos related to

Sort By:
Pageof 7
Current HIV Research|January 5, 2011
Long-term safety from the raltegravir clinical development programHedy Teppler, Deborah D Brown, Randi Y Leavitt, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 30, 2012
Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004)Eduardo Gotuzzo, Martin Markowitz, Winai Ratanasuwan, et al.
The Lancet. HIV|December 12, 2018
Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trialSharon Nachman, Carmelita Alvero, Hedy Teppler, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 24, 2019
Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus-1: An Integrated Safety AnalysisMelanie Thompson, Chloe Orkin, Jean-Michel Molina, et al.
Antiviral Therapy|October 29, 2014
Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infectionJoseph J Eron, David A Cooper, Roy T Steigbigel, et al.
Journal of Clinical Pharmacology|March 11, 2015
Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of ageMatthew L Rizk, Lihong Du, Chantelle Bennetto-Hood, et al.
The Journal of Antimicrobial Chemotherapy|April 26, 2005
In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART)David L Paterson, Flávia Rossi, Fernando Baquero, et al.
Journal of the International AIDS Society|November 14, 2014
Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patientsJosep M Gatell, Javier O Morales-Ramirez, Debbie P Hagins, et al.
The New England Journal of Medicine|October 2, 2004
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropeniaThomas J Walsh, Hedy Teppler, Gerald R Donowitz, et al.
The Lancet. HIV|December 23, 2023
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trialsChloe Orkin, Jean-Michel Molina, Pedro Cahn, et al.
Pageof 7